In the early 2000s, resveratrol looked like it might be the molecule that cracked longevity. A polyphenol found in red wine, it activated the same sirtuins that calorie restriction activates, extended lifespan in every model organism tested, and set off a pharmaceutical gold rush that ended with a $720 million acquisition. Then the human data arrived — and it was considerably more complicated.
This guide covers what resveratrol actually does, where the science stands after two decades of research, why almost nobody absorbs enough of it to matter, and what you should do if you still want to take it.
In 1992, epidemiologists Serge Renaud and Michel de Lorgeril published a paper in The Lancet that became one of the most-cited nutrition studies of the decade. They had followed 605 men who had survived a first myocardial infarction and found that those assigned to a Mediterranean-style diet — rich in olive oil, vegetables, and notably wine — had a 73% lower risk of cardiac death over two years compared to those on a Western diet. The data was striking enough that the trial was stopped early on ethical grounds.
The "French Paradox" — the observation that French people had relatively low rates of cardiovascular disease despite a diet high in saturated fat — had been circling the epidemiological literature for years. Renaud and de Lorgeril's work gave it scientific credibility and pointed at red wine as a plausible mediating variable. The question was: which component of wine was doing the work?
Resveratrol — trans-3,5,4'-trihydroxystilbene — had been identified in grape skins as a plant defense compound as far back as 1976. By the late 1990s, researchers were noting its antioxidant and anti-platelet properties in cell culture. It was a plausible candidate. The problem, which would take another decade to fully appreciate, is that a glass of red wine contains roughly 1–2mg of resveratrol, an amount that the liver processes and excretes within minutes of ingestion. The French paradox, if it exists at all, almost certainly isn't explained by resveratrol at supplemental doses delivered through wine.
Understanding why resveratrol attracted so much serious scientific attention requires understanding sirtuins. SIRT1 is a NAD+-dependent deacetylase — an enzyme that removes acetyl groups from target proteins, and in doing so, regulates a cascade of cellular processes linked to aging, metabolism, and stress resistance.
When SIRT1 is active, it deacetylates several key targets:
Resveratrol also independently activates AMPK (AMP-activated protein kinase), often called the cell's "fuel gauge." AMPK activation suppresses mTOR signaling, promotes autophagy, and shifts cells into a metabolic state that resembles mild energy restriction — the same state that extends lifespan in model organisms. This is one reason resveratrol is sometimes described as a calorie restriction mimetic.
The anti-inflammatory angle runs through both pathways. By inhibiting NF-κB (via SIRT1) and suppressing COX-2 expression (through direct polyphenol activity), resveratrol damps down the chronic low-grade inflammation that characterizes biological aging — what researchers now call "inflammaging."
The modern resveratrol story begins with a 2003 paper in Nature by Konrad Howitz, David Sinclair, and colleagues at Harvard. They reported that resveratrol activated Sir2 — the yeast homolog of SIRT1 — and extended replicative lifespan in Saccharomyces cerevisiae by 24–59% depending on the strain and concentration. The effect was dependent on Sir2; strains lacking the gene showed no extension. The implication was clear: a small molecule could mimic the effects of calorie restriction by directly activating a conserved longevity pathway.
Nature, 425(6954). Resveratrol extended yeast replicative lifespan by 24–59% in a Sir2-dependent manner. The paper proposed that small molecule sirtuin activators could mimic caloric restriction. It was cited over 3,000 times and triggered a decade of follow-up research.
The mouse data arrived three years later. In 2006, Joseph Baur, David Sinclair, and colleagues published results in Nature showing that resveratrol supplementation in middle-aged mice fed a high-fat diet extended their survival, improved insulin sensitivity, increased motor function, and produced a gene expression signature in muscle and adipose tissue that strongly resembled caloric restriction. Obese mice on resveratrol lived as long as lean controls. The paper's abstract contained the phrase "resveratrol shifts the physiology of middle-aged mice on a high-fat diet towards that of mice on a standard diet" — a sentence that appeared in thousands of press releases.
GlaxoSmithKline acquired Sirtris Pharmaceuticals — David Sinclair's spin-out company developing sirtuin activators — for $720 million in 2008. It was one of the largest acquisitions in the nascent longevity space and a clear signal that pharmaceutical companies believed sirtuin activation was a druggable longevity pathway. Resveratrol, for a brief period, was the most-discussed supplement in geroscience.
The story gets considerably messier from here.
In 2005, Marcie Borra and colleagues at the University of Wisconsin published a paper in Biochemistry challenging the core finding. They found that when they tested resveratrol's effect on SIRT1 using the same fluorescent substrate used in the Howitz 2003 assay, resveratrol appeared to be a potent activator. But when they replaced the fluorescent peptide with a native substrate — one without an attached fluorescent tag — the activation disappeared almost entirely. Their conclusion was stark: resveratrol was not directly activating SIRT1 in a biologically meaningful way; it was interacting with the fluorescent label in the assay.
This sparked a years-long controversy in the sirtuin field. Subsequent work — including papers from Sinclair's own lab and from pharmaceutical groups — eventually provided evidence that resveratrol can activate SIRT1 on native substrates under certain conditions, but the strength of the effect and its physiological relevance remain debated. The consensus shifted: resveratrol may activate SIRT1, but not as potently or directly as initially believed, and AMPK activation may account for more of its observed metabolic effects.
In 2012, Dipak Das — a University of Connecticut researcher who had published dozens of papers on resveratrol's cardiovascular benefits — was found guilty of 145 counts of data fabrication and falsification by the university's investigative committee. More than two dozen of his papers were retracted. While Das's work was a small subset of the overall resveratrol literature, the scandal damaged the field's credibility at precisely the moment pharmaceutical skepticism was growing.
GSK's sirtuin activator program — which produced more potent synthetic analogs of resveratrol called STACs (sirtuin-activating compounds) — ran clinical trials for SRT2104 and SRT2379 in conditions including type 2 diabetes, psoriasis, and COPD. Results were largely disappointing. The compounds showed limited efficacy at tolerable doses, and the program was wound down. GSK eventually closed the Sirtris unit in 2013, writing off most of the acquisition value. The $720 million bet had not paid off.
The human clinical literature on resveratrol is smaller than the animal literature and more ambiguous in its findings. Here are the key trials:
British Journal of Nutrition. 19 patients with type 2 diabetes received 5mg resveratrol twice daily for 4 weeks. The resveratrol group showed significantly improved insulin sensitivity (HOMA-IR decreased by ~10%) and reduced urinary ortho-tyrosine excretion (a marker of oxidative stress). Small trial, short duration, low dose — but a positive signal.
Cell Metabolism. 11 obese but otherwise healthy men received 150mg/day resveratrol for 30 days in a crossover design. Resveratrol supplementation produced a gene expression signature in muscle tissue resembling caloric restriction, improved mitochondrial function (increased SIRT1 and PGC-1α activity), reduced resting metabolic rate, lowered blood pressure, and reduced markers of inflammation. The paper was broadly positive and is one of the most-cited human studies in the resveratrol literature.
Cell Metabolism. 29 postmenopausal women with normal glucose tolerance received 75mg resveratrol twice daily (150mg/day) for 12 weeks. Despite adequate dosing and duration, resveratrol had no effect on insulin sensitivity, mitochondrial function, or any metabolic endpoint measured. The contrast with Timmers 2011 was striking and suggested that resveratrol's effects may be population-specific — relevant only in metabolically compromised individuals, not in metabolically healthy ones.
The broader literature follows a similar pattern: studies in people with metabolic dysfunction (obesity, pre-diabetes, cardiovascular risk) tend to show modest positive effects; studies in healthy or lean populations tend to show little or nothing. A 2015 meta-analysis by Liu et al. in American Journal of Clinical Nutrition covering 9 RCTs found resveratrol significantly reduced fasting glucose and insulin in diabetic patients but not in non-diabetic controls.
One potentially important finding: a 2013 paper by Olshansky and colleagues in JAMA Internal Medicine found that higher urinary resveratrol metabolites in a community-dwelling elderly population were actually associated with higher all-cause mortality over 9 years of follow-up. This observational finding — almost certainly confounded by dietary patterns and reverse causation — was widely misreported but serves as a reminder that the epidemiology is not straightforwardly supportive.
The single most important reason human trials underperform animal studies is bioavailability — specifically, the lack of it.
When you swallow standard resveratrol powder, the following happens with remarkable speed: intestinal cells and gut bacteria begin conjugating trans-resveratrol into glucuronide and sulfate metabolites before it even reaches systemic circulation. What does reach the portal vein undergoes rapid first-pass hepatic metabolism. Peak plasma concentrations of free resveratrol typically appear within 30–90 minutes of ingestion and fall back to near-baseline within 3–4 hours. Less than 1% of an oral resveratrol dose circulates as free, unconjugated resveratrol — the biologically active form.
Practically speaking, this means a 500mg dose of standard resveratrol powder might deliver less than 5mg of free resveratrol to target tissues. Mice in the Baur 2006 study received resveratrol mixed into their food at a concentration equivalent to roughly 350mg/kg body weight per day — for a 70kg human, a daily dose of around 24,000mg. Dosing 500–1000mg, as most supplements provide, is orders of magnitude lower, even before accounting for the species differences in metabolism.
Several formulation strategies meaningfully improve bioavailability:
Even with the best formulations, free resveratrol exposure in humans remains a fraction of the concentrations used in cell culture and rodent studies. This is the core biological reality that the supplement marketing rarely acknowledges.
Pterostilbene is a naturally occurring analog of resveratrol found primarily in blueberries and grapes. It differs structurally in two key ways: two hydroxyl groups on the resveratrol molecule are replaced by methoxy groups, making the molecule significantly more lipophilic (fat-soluble).
| Property | Trans-Resveratrol | Pterostilbene |
|---|---|---|
| Oral bioavailability | <1% (standard); up to 5–8% (optimized formulation) | ~80% (estimated in animal models; 4–10x higher than resveratrol in direct comparisons) |
| Plasma half-life | ~1–3 hours | ~7 hours (longer due to reduced glucuronidation) |
| Blood-brain barrier penetration | Low | Significantly higher (lipophilicity advantage) |
| SIRT1 activation | Yes (debated potency) | Yes (comparable mechanism) |
| AMPK activation | Yes | Yes |
| Typical dose | 500mg–1g/day | 50–150mg/day |
| Human RCT data | More extensive (20+ RCTs) | Limited (fewer studies) |
The key practical advantage of pterostilbene is that far more of it actually reaches systemic circulation. A 2013 study by Kosuru et al. found pterostilbene produced similar cardiovascular and metabolic effects to resveratrol in rodent models at substantially lower doses. The longer half-life means more sustained tissue exposure throughout the day.
The tradeoff is that pterostilbene has a smaller human clinical evidence base. Most of the mechanistic understanding is extrapolated from resveratrol research or from animal studies. One notable human signal: a 2014 RCT by Riche et al. in Evidence-Based Complementary and Alternative Medicine found pterostilbene (100–250mg/day) significantly lowered systolic blood pressure in adults with metabolic syndrome, with an effect size comparable to low-dose antihypertensives.
For individuals primarily concerned with central nervous system benefits — cognitive aging, neuroinflammation — pterostilbene's superior blood-brain barrier penetration makes it the more rational choice. For those focused on peripheral metabolic effects, either compound may work if bioavailability is addressed.
David Sinclair has been public about his personal supplement stack, which includes both NMN and resveratrol taken together each morning. The rationale is mechanistically coherent: NMN raises NAD+ levels, which provides the substrate SIRT1 requires to function. Resveratrol activates SIRT1 directly (or via AMPK-mediated pathways). The two compounds address different bottlenecks in the same pathway.
Think of it this way: SIRT1 is an enzyme that needs both fuel (NAD+) and activation (resveratrol/AMPK signaling) to run at full capacity. Providing only one without the other may leave the pathway underperforming. The combination hypothesis has not been formally tested in an RCT, but it is biologically plausible and the safety profile of both compounds taken together is acceptable.
Sinclair's Reported Morning Protocol
1g NMN + 1g trans-resveratrol dissolved in a small amount of Greek yogurt or olive oil. The fat in the yogurt or oil is key — resveratrol is poorly absorbed without dietary fat present. He takes this in the morning without other food. This is a personal protocol, not a clinical recommendation.
The yogurt or olive oil co-administration isn't incidental — it's the delivery mechanism. Resveratrol has extremely low water solubility. Dissolving or suspending it in fat before ingestion dramatically improves uptake. Taking resveratrol tablets with a glass of water on an empty stomach is one of the least effective ways to dose it.
The most commonly studied doses in human trials range from 150mg to 1g/day of trans-resveratrol. Given the bioavailability constraints, most practitioners working in this space use 500mg–1g/day of high-quality trans-resveratrol taken with a fatty meal. Lower doses (150–250mg) may be sufficient with micronized or liposomal formulations.
For pterostilbene, the higher bioavailability means lower doses are appropriate: 50–150mg/day is the typical range, split into one or two doses with meals.
Resveratrol has a reasonably clean safety profile at doses up to 1g/day in short-term studies. Higher doses (2.5–5g/day) have been associated with gastrointestinal side effects including nausea and diarrhea in some participants.
⚠ Drug Interaction Warning
Resveratrol inhibits CYP2C9, one of the primary cytochrome P450 enzymes responsible for metabolizing warfarin (Coumadin) and several other anticoagulants. Co-administration can increase warfarin plasma levels and significantly elevate bleeding risk. If you are taking warfarin, other anticoagulants, or any medication metabolized by CYP2C9 (including phenytoin, celecoxib, and some NSAIDs), do not take resveratrol without physician oversight and INR monitoring.
Resveratrol also inhibits CYP3A4 at higher doses, which may affect the metabolism of statins, calcium channel blockers, and certain immunosuppressants. Consult your physician or pharmacist before combining resveratrol with prescription medications.
Resveratrol is a phytoestrogen — it can bind estrogen receptors, though with much lower affinity than endogenous estrogens. This theoretical concern has not translated into observed clinical problems at typical supplement doses, but individuals with estrogen-sensitive cancers or conditions should discuss use with their physician.
Some evidence suggests resveratrol may blunt the adaptive stress response to acute exercise when taken immediately post-workout — a finding from a 2013 Bjornsen et al. trial in older men. The proposed mechanism is that resveratrol's antioxidant activity suppresses the ROS signaling that drives training adaptation. To avoid this potential interaction, consider taking resveratrol in the morning rather than around exercise sessions.
The animal data is compelling — extended lifespan, improved metabolic function, calorie restriction mimicry, and SIRT1/AMPK activation are all well-documented in model organisms. The human RCT evidence is considerably thinner and most positive effects appear in metabolically compromised populations rather than healthy individuals.
Resveratrol is a reasonable addition at 500mg/day with a fatty meal if you're already optimizing NAD+ levels and lifestyle fundamentals. It is not a substitute for exercise, caloric discipline, or sleep. It is unlikely to do much of anything at typical doses taken without fat. The bioavailability problem is real and should drive your formulation choices.
Pterostilbene may be a better choice for most people given its superior bioavailability, longer half-life, and blood-brain barrier penetration — particularly for cognitive aging support. The evidence base is smaller, but the pharmacokinetics argue in its favor.
If you decide to add resveratrol or pterostilbene to your stack, formulation quality matters significantly. Look for trans-resveratrol (the active isomer) rather than unspecified "resveratrol," and prefer micronized or liposomal formulations over standard powder capsules.
For resveratrol, prioritize products specifying trans-resveratrol content, third-party testing, and at least 500mg per serving. Take with a meal containing olive oil, avocado, nuts, or full-fat yogurt.
→ View Trans-Resveratrol on AmazonPterostilbene supplements are widely available at 50–100mg doses. Look for products without unnecessary fillers. 100mg once daily with breakfast is a reasonable starting point.
→ View Pterostilbene on AmazonDisclosure: LongevityLab participates in the Amazon Associates program. Links above are affiliate links — we may earn a commission at no additional cost to you. This does not influence our editorial assessments.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.